DMK Pharmaceuticals Corp
OTC:DMKPQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DMK Pharmaceuticals Corp
Total Liabilities & Equity
DMK Pharmaceuticals Corp
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DMK Pharmaceuticals Corp
OTC:DMKPQ
|
Total Liabilities & Equity
$9m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
10%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities & Equity
$199.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities & Equity
$90B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities & Equity
$208.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities & Equity
$136.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities & Equity
$112.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
DMK Pharmaceuticals Corp
Glance View
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
See Also
What is DMK Pharmaceuticals Corp's Total Liabilities & Equity?
Total Liabilities & Equity
9m
USD
Based on the financial report for Sep 30, 2023, DMK Pharmaceuticals Corp's Total Liabilities & Equity amounts to 9m USD.
What is DMK Pharmaceuticals Corp's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
10%
Over the last year, the Total Liabilities & Equity growth was -26%. The average annual Total Liabilities & Equity growth rates for DMK Pharmaceuticals Corp have been -41% over the past three years , -34% over the past five years , and 10% over the past ten years .
